Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 6:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Hylenex Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Descriptive Study of Cardiac Output During Rehydration With Recombinant Human Hyaluronidase in Pediatrics

NCT01139294
View directory record Official record
Conditions
Dehydration, Cardiac Output, Pediatrics
Interventions
Hylenex
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
2 Months to 3 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 1, 2018 · Synced Oct 18, 2026, 6:35 PM EDT
Completed Phase 2 Interventional Results available

Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus

NCT00883558
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Insulin Lispro, regular human insulin, recombinant human hyaluronidase PH20, Insulin glargine
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
8
States / cities
Aurora, Colorado • Miami, Florida • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Oct 18, 2026, 6:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Safety, Tolerability and PK Study of Ondansetron and Hylenex Recombinant in Healthy Volunteers

NCT01572012
View directory record Official record
Conditions
Healthy
Interventions
Ondansetron, Ondansetron + Hylenex, Zofran ODT, Ondansetron solution
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
19 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2014 · Synced Oct 18, 2026, 6:35 PM EDT
Completed Phase 2 Interventional Results available

Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus

NCT01194245
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Insulin lispro, recombinant human hyaluronidase PH20, Insulin aspart, Insulin glulisine, Insulin glargine
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
19
States / cities
Escondido, California • La Jolla, California • San Mateo, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 18, 2026, 6:35 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Study of In-line Pressure Using Various Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase (INFUSE-AT1A)

NCT01116102
View directory record Official record
Conditions
Dehydration
Interventions
Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution
Drug
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Oct 24, 2011 · Synced Oct 18, 2026, 6:35 PM EDT
Not yet recruiting Early Phase 1 Interventional

Hyaluronidase for Sclerodactyly in Systemic Sclerosis Trial

NCT07697274
View directory record Official record
Conditions
Systemic Sclerosis, Sclerodactyly
Interventions
Hyaluronidase (Hylenex)
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 18, 2026, 6:35 PM EDT
Completed Phase 3 Interventional

INFUSE Morphine Study

NCT00593281
View directory record Official record
Conditions
Pain
Interventions
Hylenex
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2008 · Synced Oct 18, 2026, 6:35 PM EDT
Completed Phase 4 Interventional Results available

Subcutaneous Rehydration Compared to Intravenous Rehydration

NCT00773175
View directory record Official record
Conditions
Dehydration
Interventions
recombinant human hyaluronidase
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
30 Days to 10 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
25
States / cities
Hartford, Connecticut • Orlando, Florida • Tampa, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 18, 2026, 6:35 PM EDT
Active, not recruiting Phase 2 Interventional

Peripheral Modulation of Muscle Stiffness and Spasticity

NCT03306615
View directory record Official record
Conditions
Muscle Spasticity
Interventions
Hyaluronidase, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 18, 2026, 6:35 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Subcutaneous Hydration Enabled by Human Recombinant Hyaluronidase (Hylenex)

NCT00656370
View directory record Official record
Conditions
Healthy
Interventions
recombinant human hyaluronidase
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Oct 18, 2026, 6:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic and Glucodynamic Crossover Study of Subcutaneously (SC) Administered Insulin Lispro + Recombinant Human Hyaluronidase (rHuPH20) and Regular Human Insulin + rHuPH20 Compared to Insulin Lispro Alone

NCT00862849
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Insulin Lispro, Regular Human Insulin, rHuPH20
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2014 · Synced Oct 18, 2026, 6:35 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase

NCT00807885
View directory record Official record
Conditions
Dehydration
Interventions
hylenex-facilitated subcutaneous Lactated Ringer's infusion
Drug
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
18 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Lincoln, Nebraska • Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 26, 2011 · Synced Oct 18, 2026, 6:35 PM EDT
Completed Phase 2 Interventional Results available

Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM)

NCT00916357
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Humalog, Humulin-R, Recombinant human hyaluronidase PH20 (rHuPH20)
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2014 · Synced Oct 18, 2026, 6:35 PM EDT
Completed Phase 2 Interventional Results available

Effects of Subcutaneous Hyaluronidase Administration on Psoriatic Plaques

NCT01987609
View directory record Official record
Conditions
Psoriasis
Interventions
Hylenex, Normal Saline
Drug
Lead sponsor
Tissa Hata, MD
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 4, 2019 · Synced Oct 18, 2026, 6:35 PM EDT
Completed Not applicable Interventional

Efficacy of Hylenex in the Treatment of Pain Among Hospice Patients

NCT00547664
View directory record Official record
Conditions
Pain Management
Interventions
Hylenex recombinant , morphine, saline, Saline
Drug · Other
Lead sponsor
HPC Healthcare, Inc.
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
3
States / cities
Lakeland, Florida • Tampa, Florida • Temple Terrace, Florida
Source: ClinicalTrials.gov public record
Updated Feb 28, 2014 · Synced Oct 18, 2026, 6:35 PM EDT
Completed Phase 4 Interventional Results available

CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)

NCT01848990
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Commercial Hylenex® recombinant (hyaluronidase human injection), Precommercial Hylenex recombinant (hyaluronidase human injection), Insulin lispro, Insulin aspart, Insulin glulisine
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
39
States / cities
Concord, California • Encino, California • Escondido, California + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 18, 2026, 6:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Administered Humulin R and Humalog With or Without rHuPH20

NCT00803972
View directory record Official record
Conditions
Healthy Volunteers
Interventions
rHuPH20, Insulin Human Injection, Insulin Lispro Injection
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Oct 18, 2026, 6:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM)

NCT01275131
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin aspart, Recombinant human hyaluronidase PH20 (rHuPH20)
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jul 25, 2014 · Synced Oct 18, 2026, 6:35 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Phase IIIB Dose Comparison Study of Subcutaneous Hydration With and Without Human Recombinant Hyaluronidase (HYLENEX) in Volunteer Subjects

NCT00311519
View directory record Official record
Conditions
Healthy
Interventions
Hylenex
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2006 · Synced Oct 18, 2026, 6:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Pharmacokinetic and Glucodynamic Study of Subcutaneously Administered Insulin Analogs With rHuPH20 Compared to Insulin Analogs Alone

NCT00979875
View directory record Official record
Conditions
Healthy
Interventions
Recombinant human hyaluronidase PH20 (rHuPH20), Insulin lispro, Insulin glulisine, Insulin aspart
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Oct 18, 2026, 6:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

EASI Access II --- Follow-up Study to the EASI Access Trial

NCT00740727
View directory record Official record
Conditions
Disaster Medicine, Difficult Intravenous Access, Dehydration
Interventions
Human recombinant hyaluronidase (HRH), Enzymatically Augmented Subcutaneous Infusion (EASI) line placement
Drug · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2009 · Synced Oct 18, 2026, 6:35 PM EDT
Completed Phase 2 Interventional Results available

Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus

NCT01194258
View directory record Official record
Conditions
Diabetes Mellitus, Type II
Interventions
Insulin lispro, Insulin aspart, Recombinant human hyaluronidase PH20, Insulin glulisine, Insulin glargine
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
22
States / cities
Concord, California • Encino, California • Escondido, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Oct 18, 2026, 6:35 PM EDT
Completed Phase 4 Interventional Results available

Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase

NCT01526733
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Sham Injection, Recombinant human hyaluronidase PH20, Insulin aspart, Insulin lispro
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 18, 2026, 6:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog® With and Without Recombinant Human Hyaluronidase (rHuPH20)and Humulin-R® With and Without rHuPH20

NCT00705536
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Humalog, Humulin-R, Recombinant human hyaluronidase PH20 (rHuPH20)
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 18, 2026, 6:35 PM EDT